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patients who begin with low and high levels and regardless of
ﬁnal level achieved. METHODS: A cohort of 27,660 patients
with coronary artery disease, peripheral vascular disease, or dia-
betes mellitus were selected and followed retrospectively for their
ﬁrst myocardial infarction or revascularization recorded in 
the New England Veterans Affairs database. Pre-outcome 
low-density lipoprotein cholesterol reduction was categorized as
follows: <10 mg/dl, reference; 10–39 mg/dl, small reduction;
40–69 mg/dl, moderate reduction; >70 mg/dl, large reduction.
Cox proportional hazards was used to determine hazard ratios
for each category of lipid reduction compared to reference and
stratiﬁed by high or low initial LDL-C, adjusting for initial LDL-
C, statin use, age, gender, and co morbidities. RESULTS: Among
patients with initial LDL-C above the median of 133 mg/dL,
hazard ratios (95% conﬁdence intervals) for small, moderate,
and large reductions compared to reference were 0.90
(0.85–0.96), 0.84 (0.79–0.90), and 0.76 (0.70–0.83) respectively.
A total of 3448 or 24% of such patients achieved a ﬁnal level
<100 mg/dL. Among patients with initial levels below the
median, hazard ratios (95% conﬁdence intervals) for small, 
moderate, and large reductions were 0.90 (0.85–0.96), 0.87
(0.79–0.96), and 0.76 (0.56–1.05) respectively. A total of 5492
or 40% of such patients achieved ﬁnal level <100 mg/dL. CON-
CLUSION: These data suggest that magnitude of reduction in
low-density lipoprotein cholesterol is proportional to degree of
reduction in cardiovascular risk, and that this effect holds both
for patients with initially low or high lipid levels, regardless of
whether a ﬁnal LDL-C of <100 mg/dL was achieved.
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OBJECTIVES: The lipid-lowering arm of ASCOT demonstrated
that in hypertensive patients, in primary prevention who are not
conventionally deemed dyslipidaemic and with at least three car-
diovascular risk factors (CVRF), atorvastatin ten mg conferred
a reduction in CV morbimortality. There are no data regarding
the prevalence of these patients among the hypertensives in
Spain. The objective is to determine the prevalence of the patient
as deﬁned in the ASCOT among the Spanish hypertensives.
METHODS: Data from 2004 to 2005 of 6309 hypertensives
from Spanish primary care centres were studied. We analyzed the
following variables: left-ventricular hypertrophy, other speciﬁed
abnormalities on EKG, type 2 diabetes, peripheral arterial
disease, previous stroke, gender, age, microalbuminuria,
smoking, ratio total cholesterol/HDL-cholesterol, and premature
family history of CHD. We analyzed the Number of CVRF as
deﬁned in ASCOT and the percentage of patients with CVRF ≥3
(with normal TC and in primary prevention). RESULTS: Of the
6309 patients, 2528 (40%) had history of CHD and/or heart
failure and/or TC >250 mg/dl and/or a statin treatment. The
presence of ASCOT-CVFR ≥3 was analyzed in the 3781 remain-
ing ones. The percentage of additional CVRF relative to these
3781 patients was: 0 FRCV: 4.3%; 1 FRCV: 24.6%; 2 FRCV:
30.4%; 3 FRCV: 22.2%; 4 FRCV: 11.8%; 5FRCV: 5.1%; 6
FRCV: 1.3%; 7 FRCV: 0.3%; 8 FRCV: 0.03%. There were 1540
patients (40.7%) with CVRF ≥3. This percentage, in relation to
the whole population of hypertensives (6309) was 24.4%. CON-
CLUSIONS: Because of the retrospective nature of the design, it
is advisable to be prudent in the external generalization. Never-
theless a high prevalence (at least 40.7%) of the ASCOT-patient
(CVRF ≥3), relative to a population of Spanish hypertensive
patients in primary prevention, not treated with statins and with
total cholesterol ≤250 mg/dL, have been demonstrated.
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OBJECTIVE: The ALLHAT study, published in December of
2002, indicated improved outcomes for hypertensive patients on
thiazide diuretics. This study evaluated the utilization of thi-
azides in hypertensives in the year before and after the publica-
tion of these results in a national primary care database.
METHODS: A retrospective review of an electronic medical
record (EMR) database (GE Medical Systems Centricity) con-
taining the ambulatory health record data for over 3.2 million
individuals was conducted. Patients with an ICD-9 code for
hypertension (HPTN) and a GPI code for thiazide diuretic were
identiﬁed in calendar years 2002 and 2003. Patients in each year
on thiazides, on or after HPTN diagnosis, were taken as a per-
centage of those with hypertension. RESULTS: In the year 2002
there were 81,916 patients with hypertension, 40,392 patients
on thiazide diuretics and 17,520 patients with both. Of those,
15,253 had their thiazide prescription on or after the date of
HPTN diagnosis. In 2003 there were 114,347 patients with
HPTN, 56,796 on thiazides, 26,199 with HPTN and 22,321
with their thiazide prescription on or after HPTN diagnosis. The
percent of hypertensives on thiazides was 18.62% in 2002 and
19.52% in 2003 with an increase of 0.9% in thiazide use in
patients with hypertension. CONCLUSION: Despite published
evidence of improved outcomes for hypertensive patients treated
with thiazide diuretics, the increase utilization in a primary care
database was modest.
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OBJECTIVES: To determine the association and The rapeutic
control goals of certain cardiovascular risk factors (CVRF) in a
Spanish primary care population. METHODS: A retrospective
study was performed based on patient’s data from ﬁve ambula-
tory primary care centres. Patients aged >18 years, attended
during year 2004, with at least one major CVRF were included.
The following variables were analysed: age, sex, main diagnosis
(hypertension, dyslipidemia, diabetes and/or cardiovascular
event [ECV]) and clinical parameters (systolic blood pressure,
diastolic blood pressure, LDLc, HbA1c). Therapeutic control
goals were established according to NCEP-ATP III. A bivariant
analysis and a binary logistic regression model were performed
to ﬁt the model. The statistical program SPSS was used with a
5% signiﬁcance level. RESULTS: A total of 15,470 patients had
at least one CVRF. Mean age was 61.3 ± 14.3; 53.7% were
female and 14.2% had a history of CVD. The diagnosis was
hypertension in 60.6%, diabetes in 26.7% and hipercoles-
terolemia in 49.5%. The presence of CVRF >3 was conﬁrmed in
5.8% and CVD in 28.3%. The percentage of patients who
